1560 Trapelo Road
Waltham, MA 02451
United States
781 786 8230
https://www.dyne-tx.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 143
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Ms. Susanna Gatti High M.B.A. | Chief Operating Officer | 754,1k | S.O. | 1968 |
Dr. Jonathan McNeill M.D. | Chief Business Officer | 662,34k | S.O. | 1985 |
Mr. John G. Cox M.B.A. | CEO, President & Director | S.O. | S.O. | 1963 |
Dr. Romesh Subramanian Ph.D. | Co-Founder & Advisor | 565,17k | S.O. | 1965 |
Mr. Richard William Scalzo M.B.A. | Senior VP and Head of Finance & Administration | S.O. | S.O. | 1986 |
Mr. John Najim M.B.A. | Chief Technical Officer | S.O. | S.O. | S.O. |
Dr. Oxana Beskrovnaya Ph.D. | Chief Scientific Officer | 631,08k | S.O. | 1961 |
Ms. Amy Reilly | Senior VP and Head of Corporate Communications & Investor Relations | S.O. | S.O. | 1974 |
Mr. Daniel Wilson | Senior VP & Head of Legal | S.O. | S.O. | 1972 |
Ms. Kate Mitchell | VP & Head of Human Resources | S.O. | S.O. | S.O. |
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
L’ISS Governance QualityScore de Dyne Therapeutics, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 6; Société : 7; Droits des actionnaires : 8; Compensation : 8.